2022 Annual Report
We are a San Diego-based clinical-stage pharmaceutical company committed to the development and commercialization of novel, best-in-class, cancer therapies intended to improve outcomes for patients. Our approach is to fully understand and leverage the properties of our drug candidates to optimize the balance between efficacy and tolerability to best meet the needs of patients with cancer.
Our portfolio of drug candidates contains multiple clinical-stage assets, including zandelisib, currently being evaluated in multiple clinical trials which may support marketing applications with the U.S. Food and Drug Administration and regulatory authorities outside the United States.